A meta-analysis of the effects of venlafaxine on anxiety associated with depression

Journal of Clinical Psychopharmacology

Volumn 18, Issue 2, 1998, Pages 136-144

  Rudolph, Richard L ^a   Entsuah, Richard ^a   Chitra, Rohini ^a  

^a WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PLACEBO; TRAZODONE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOMATIZATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES;

EID: 0031898548     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199804000-00006     Document Type: Article

References (31)

1. Sanderson WC, Beck AT, Beck J. Syndrome comorbidity in patients with major depression or dysthymia: prevalence and temporal relationships. Am J Psychiatry 1990;147:1025-8.
2. Di Nardo P, Barlow D. Syndrome and symptom co-occurrence in the anxiety disorders. In: Maser J, Cloninger CR, eds. Comorbidity of mood and anxiety disorders. Washington, DC: American Psychiatric Press, 1990:205-30.
3. Zung W, Magruder-Habib K, Velez R, Alling W. The comorbidity of anxiety and depression in general medical patients: a longitudinal study. J Clin Psychiatry 1990;951[suppl]:77-80.
4. Ormel J, Koeter M, van den Brink W, van de Willige G. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991;48:700-6.
5. Van Valkenburg C, Akiskal H, Puzantian V, Rosenthal T. Anxious depressions: clinical, family history, and naturalistic outcome comparisons with panic and major depressive disorders. J Affect Disord 1984;6:67-82.
6. Grunhaus L, Harel Y, Krugler T, Pande A, Haskett R. Major depressive disorder and panic disorder. Clin Neuropharmacol 1988; 11:454-61.
7. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
8. Yardley JP, Morris H, Husbands GE, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andru T, Fletcher H, III, James NGJ, Sielecki AR. 2-phenyl-2-(1-hydroxycycloalkyl) ethylamine derivatives: synthesis and antidepressant activity. J Med Chem 1990;33: 2899-905.
9. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55[suppl A]:62-8.
10. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
11. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry (in press).
12. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74.
13. Shrivastava R, Patrick R, Scherer N, Upton GV. A dose-response study of venlafaxine [abstract]. Neuropharmacol 1994;10:2215. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Meeting, June 4, 1994. Washington, DC.
14. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55: 104-8.
15. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
16. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8.
17. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
18. Montgomery SA. Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 1995;10[suppl 2]:21-7.
19. Entsuah R, Rudolph R, Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a metaanalysis. Psychopharmacol Bull 1995;31:759-66.
20. Rudolph R, Entsuah R, Chitra R. The effects of venlafaxine on anxiety associated with depression. Presented at the 2nd International Conference of New Directions in Affective Disorders. Jerusalem, Israel: September 3-8, 1995.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. Montgomery SA, sberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
23. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985;21:839-43.
24. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-26.
25. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
26. Clerc GE, Ruimy P, Verdeau-Pailläs J on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:139-43.
27. Entsuah R, Rudolph R, Derivan A, Rickels K. A low relapse rate confirms the long-term efficacy of venlafaxine in the treatment of major depression [abstract].Presented at the 32nd Annual Meeting, American College of Neuropsychopharmacology. Honolulu, HA: December 1993.
28. Schapira K, Roth M, Kerr TA, Gurney C. The prognosis of affective disorders: the differentiation of anxiety states from depressive illnesses. Br J Psychiatry 1972;121:175-81.
29. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141-51.
30. D'Agostino RB, Weintraub M. Meta-analysis. A method for synthesizing research. Clin Pharmacol Ther 1995;58:605-16.
31. Geller NL, Proschan M. Meta-analysis of clinical trials: consumer's guide. J Biopharm Stat 1996;6:377-94.